NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
55 trialsNCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT00492999 2025-08-17
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05476796 2024-10-24
LOGICAN
UNICANCER
Phase 2 Recruiting
NCT06538623 2024-08-27
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
Phase 2 Recruiting
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT04694183 2024-02-07
The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer
The First Hospital of Jilin University
Phase 2 Completed
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT05237349 2024-01-05
Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT03487016 2022-09-08
FOOTPATH
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT01442649 2022-01-11
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
UNICANCER
Phase 2 Completed
NCT00297596 2021-10-28
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT02128243 2021-03-26
MATEO
AIO-Studien-gGmbH
Phase 2 Completed
NCT00006050 2021-02-17
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
UNICANCER
Phase 2 Completed
NCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT01858649 2020-10-22
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT01387373 2020-10-05
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
Herlev Hospital
Phase 2 Completed
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT00444678 2020-04-03
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
NYU Langone Health
Phase 2 Completed
NCT01396707 2020-01-07
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
Asan Medical Center
Phase 2 Completed
NCT03585673 2018-07-17
DOSE
Dong-A University Hospital
Phase 2 Unknown
NCT00408772 2017-06-09
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
University of California, Davis
Phase 2 Withdrawn
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed
NCT02856867 2017-05-09
MEGAN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00056030 2017-01-24
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT02855788 2016-08-04
Metronomic Chemotherapy in Advanced Gastric Cancer
Huashan Hospital
Phase 2 Unknown
NCT01130805 2016-04-15
A Study of Pazopanib With CAPEOX in AGC Patients
Samsung Medical Center
Phase 2 Completed
NCT00515216 2016-01-07
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Vanderbilt University
Phase 2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT00865709 2014-12-11
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
Bayer
Phase 2 Completed
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00125034 2014-08-07
OPUS
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00408551 2013-12-19
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00950820 2013-03-04
VOXEL
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00118105 2013-01-03
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00043004 2012-09-24
Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01175291 2011-12-05
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Withdrawn
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00438737 2011-09-02
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00544349 2011-05-17
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00065117 2011-01-26
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
AstraZeneca
Phase 2 Terminated
NCT00512681 2009-09-18
TIROX2
National Cancer Center, Korea
Phase 2 Completed
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown